PT  - JOURNAL ARTICLE
AU  - Salahuddin, Salman
TI  - FINEARTS-HF: Improving outcomes in heart failure with preserved or mildly reduced ejection fraction
AID  - 10.3949/ccjm.93a.25081
DP  - 2026 May 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 273--277
VI  - 93
IP  - 5
4099  - http://www.ccjm.org/content/93/5/273.short
4100  - http://www.ccjm.org/content/93/5/273.full
SO  - Cleve Clin J Med2026 May 01; 93
AB  - The FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure, N Engl J Med 2024; 391(16):1475–1485) trial evaluated finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in patients with left ventricular ejection fraction 40% or greater. Finerenone reduced the composite risk of hospitalization for heart failure or cardiovascular death by 16% relative to placebo (rate ratio 0.84, P = .007), primarily by lowering admissions for heart failure. Finerenone is the first mineralocorticoid receptor antagonist to improve outcomes in this patient population.